2026-06-14T03:31:43Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/149862025-05-16T11:00:49Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Alderson, Mark R author Arkwright, Peter D author Bai, Xilian author Black, Steve author Borrow, Ray author Caugant, Dominique A author Dinleyici, Ener Cagri author Harrison, Lee H author Lucidarme, Jay author McNamara, Lucy A author Meiring, Susan author Sáfadi, Marco A P author Shao, Zhujun author Stephens, David S author Taha, Muhamed-Kheir author Vazquez-Moreno, Julio Alberto author Zhu, Bingqing author GMI collaborators author 2022-03 This review article incorporates information from the 4th Global Meningococcal Initiative summit meeting. Since the introduction of stringent COVID-19 infection control and lockdown measures globally in 2020, there has been an impact on IMD prevalence, surveillance, and vaccination compliance. Incidence rates and associated mortality fell across various regions during 2020. A reduction in vaccine uptake during 2020 remains a concern globally. In addition, several Neisseria meningitidis clonal complexes, particularly CC4821 and CC11, continue to exhibit resistance to antibiotics, with resistance to ciprofloxacin or beta-lactams mainly linked to modifications of gyrA or penA alleles, respectively. Beta-lactamase acquisition was also reported through horizontal gene transfer (blaROB-1) involving other bacterial species. Despite the challenges over the past year, progress has also been made on meningococcal vaccine development, with several pentavalent (serogroups ABCWY and ACWYX) vaccines currently being studied in late-stage clinical trial programmes. J Infect. 2022 Mar;84(3):289-296. 10.1016/j.jinf.2021.11.016 1532-2742 The Journal of infection 34838594 http://hdl.handle.net/20.500.12105/14986 Antibiotic resistance COVID-19 Coronavirus Invasive meningococcal disease Neisseria meningitidis Pandemic Serogroup Sexual transmission Vaccination Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review